Journal of Immunology Research

Exploration of Novel Potential Biomarkers for Cancer Immunotherapy


Publishing date
01 Jan 2023
Status
Closed
Submission deadline
09 Sep 2022

Lead Editor

1Xi’an Jiaotong University, Xi'an, China

2Sun Yat-Sen University, Guangzhou, China

3Imperial College London, London, UK

This issue is now closed for submissions.

Exploration of Novel Potential Biomarkers for Cancer Immunotherapy

This issue is now closed for submissions.

Description

In 2016, the American Society of Clinical Oncology (ASCO) named immunotherapy the “Advance of the Year”. Within a few years, it has revolutionized cancer therapy. Therefore, there is an increasing need to identify novel potential biomarkers for the complex responses of immune checkpoint inhibitors, which would further increase the treatment responses and prolong the survival of cancer patients. Biomarkers are biological/pathological molecules present in or produced by patients, which could be found in blood, tumor cells, or tissue at the genomic, cellular, and soluble levels. Such biomarkers come in different forms, for example, host genomic factors, serum proteins, and nucleic acids (DNA or RNA molecules) within tumor cells and their microenvironments. Ideal biomarkers could aid healthcare professionals to achieve optimal treatment goals and bring clinical benefits to patients.

In the past decade, multiple tumor biomarkers have been validated and are widely used in clinics with proven effectiveness. However, there is still a need to develop new strategies to improve the efficiency and accuracy of cancer treatments by identifying more reliable biomarkers. With the development of high-throughput sequencing technologies in proteomics and genomics, both single and multifactorial synergistic markers have been gradually explored for clinical purposes using a variety of biomarker strategies. For instance, mass spectrometry improved the diagnosis of hybrid tumors and bulk, as well as single-cell sequencing which improved our current understanding of tumor cell-specific markers used for early diagnosis. Identification of multiple immune-checkpoint markers that are critical for developing therapeutic targets for precise immune-oncology, would have a profound impact in the field of personalized medicine.

The aim of this Special Issue is to bring together original research and review articles focusing on exploring novel predictive biomarkers for cancer diagnosis and prognosis, with an emphasis on immunotherapy techniques.

Potential topics include but are not limited to the following:

  • Tumor genome and neoantigen-related biomarkers
  • Tumor immune microenvironment phenotype-associated biomarkers
  • Liquid biopsy biomarkers such as circulating tumor DNA or peripheral blood cell biomarkers
  • Biomarkers for tumor diagnosis and immunotherapy targets
  • Use of biomarkers for the assessment of prognosis of tumors
  • Biomarkers for predicting tumor recurrence and metastasis
  • Biomarkers for identification of tumor-associated cell types
  • The spatial-temporal changes and regulatory mechanisms involved with biomarkers
  • New methodologies including algorithms used for characterization of tumor biomarkers

Articles

  • Special Issue
  • - Volume 2022
  • - Article ID 8337048
  • - Research Article

NAV3 Is a Novel Prognostic Biomarker Affecting the Immune Status of the Tumor Microenvironment in Colorectal Cancer

Menglong Li | Zhiqiang Wang | ... | Yang Xu
  • Special Issue
  • - Volume 2022
  • - Article ID 9912732
  • - Research Article

An Integrative Analysis Revealing ZFHX4-AS1 as a Novel Prognostic Biomarker Correlated with Immune Infiltrates in Ovarian Cancer

Changchang Huang | Hongyin Cui | ... | Fen Zhao
  • Special Issue
  • - Volume 2022
  • - Article ID 2359349
  • - Research Article

Construction of Metabolic Molecular Classification and Immune Characteristics for the Prognosis Prediction of Ovarian Cancer

Kexin Wang | Hui He | Xue Feng
  • Special Issue
  • - Volume 2022
  • - Article ID 5826741
  • - Research Article

A Systematic Pan-Cancer Analysis of YY1 Aberrations and their Relationship with Clinical Outcome, Tumor Microenvironment, and Therapeutic Targets

Xinghao Fu | Feihong Ji | ... | Xinguang Qiu
  • Special Issue
  • - Volume 2022
  • - Article ID 1993023
  • - Research Article

Prediction of Necroptosis-Related Markers in Head and Neck Carcinoma by Bioinformatics

Lin Zheng | Minhui Li | ... | Honglin Dong
  • Special Issue
  • - Volume 2022
  • - Article ID 8649386
  • - Research Article

circACTG1 Promotes Hepatocellular Carcinoma Progression by Regulating miR-940/RIF1 Axis and Activating AKT/mTOR Pathway

Chunchen Wu | She Tian | ... | Chengyi Sun
  • Special Issue
  • - Volume 2022
  • - Article ID 2555647
  • - Research Article

Highly Expressing SCARA5 Promotes Proliferation and Migration of Esophageal Squamous Cell Carcinoma

Kawuli Jumai | Tangjuan Zhang | ... | Ilyar Sheyhidin
  • Special Issue
  • - Volume 2022
  • - Article ID 7212852
  • - Research Article

The Potential Diagnostic Value of Immune-Related Genes in Interstitial Fibrosis and Tubular Atrophy after Kidney Transplantation

Bin Yang | Dike Shi | ... | Yi Zhu
  • Special Issue
  • - Volume 2022
  • - Article ID 7282842
  • - Research Article

MAIP1-Related Tumor Immune Infiltration: As a Potential Prognostic Biomarker for Esophageal Cancer

Xiaoyu He | Fu Gan | ... | Dongxu Chen
  • Special Issue
  • - Volume 2022
  • - Article ID 2156204
  • - Research Article

Impact of Amarogentin on Gastric Carcinoma Cell Multiplication, Apoptosis and Migration via circKIF4A/miR-152-3p

Zhi Tan | Weining Wang | ... | Wenling Fan
Journal of Immunology Research
 Journal metrics
See full report
Acceptance rate11%
Submission to final decision121 days
Acceptance to publication27 days
CiteScore6.000
Journal Citation Indicator0.560
Impact Factor4.1
 Submit Check your manuscript for errors before submitting

Article of the Year Award: Impactful research contributions of 2022, as selected by our Chief Editors. Discover the winning articles.